Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 25:15:1640352.
doi: 10.3389/fcimb.2025.1640352. eCollection 2025.

Nanobodies in animal infectious disease control: diagnosis and therapy

Jing Wang #  1 , Tiejin Tong #  1 , Qiang Wu  1
Affiliations
Review

Nanobodies in animal infectious disease control: diagnosis and therapy

Jing Wang et al. Front Cell Infect Microbiol. .

Abstract

Animal infectious diseases threaten livestock productivity, public health, and food security. Traditional monoclonal antibodies (mAbs) face limitations in diagnostics and therapy due to their large size, instability, and high cost. Nanobodies (Nbs), derived from camelid heavy-chain antibodies, offer superior properties-small size (~15 kDa), high stability, deep tissue penetration, and cost-effective production. Nbs feature extended CDR3 loops, enabling access to cryptic epitopes, and exhibit exceptional thermal/pH stability. They are generated by immunizing camelids, cloning VHH genes, and screening via phage/yeast display. High-throughput methods (ELISA, flow cytometry) allow rapid isolation of high-affinity Nbs. Compared to mAbs, Nbs are economically produced in prokaryotic systems and engineered into multivalent or Fc-fused formats for enhanced efficacy. In diagnostics, Nbs enable sensitive, low-cost detection of pathogens like PRRSV, ASFV, and avian influenza. Nb-based competitive ELISAs and lateral flow assays improve field surveillance. Therapeutically, Nbs neutralize pathogens by targeting viral proteins (e.g., blocking PRRSV-CD163 entry) or bacterial toxins (e.g., Staphylococcus enterotoxins). Nb-Fc fusions degrade ASFV proteins via TRIM-away, while intracellular Nbs disrupt Mycobacterium ESAT-6 or Toxoplasma actin dynamics. Challenges remain in Nb affinity optimization, intracellular delivery, and in vivo half-life. Solutions include fusion with cell-penetrating peptides or viral vectors (e.g., adenoviruses). Reducing cross-species immunogenicity and scaling production are critical for broader adoption. With advances in protein engineering, Nbs hold transformative potential for preventing, diagnosing, and treating animal diseases, offering scalable solutions for global health and food security.

Keywords: ASFV; PRRSV; animal infectious diseases; diagnostics; nanobodies; phage display; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The differences between traditional monoclonal antibodies and Nbs. (A) Structural diagram of a conventional antibody, consisting of heavy and light chains. (B) Structural diagram of a nanobody.
Figure 2
Figure 2
The preparation process of Nbs.
Figure 3
Figure 3
Nb screens different surface display platforms.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abeijon C., Dilo J., Tremblay J. M., Viana A. G., Bueno L. L., Carvalho S. F. G., et al. (2018). Use of VHH antibodies for the development of antigen detection test for visceral leishmaniasis. Parasite Immunol. 40, e12584. doi: 10.1111/pim.12584, PMID: - DOI - PMC - PubMed
    1. Bates T. A., Trank-Greene M., Nguyenla X., Anastas A., Gurmessa S. K., Merutka I. R., et al. (2024). ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6-specific nanobody restricts M. tuberculosis growth in macrophages. Elife 12:RP91930. doi: 10.7554/eLife.91930, PMID: - DOI - PMC - PubMed
    1. Bezbaruah R., Chavda V. P., Nongrang L., Alom S., Deka K., Kalita T., et al. (2022). Nanoparticle-based delivery systems for vaccines. Vaccines (Basel) 10:1946. doi: 10.3390/vaccines10111946, PMID: - DOI - PMC - PubMed
    1. Broster Reix C. E., Ramanantsalama M. R., Di Primo C., Minder L., Bonhivers M., Dacheux D., et al. (2021). Intrabody-induced cell death by targeting the T. brucei cytoskeletal protein tbBILBO1. Microbiol. Spectr. 9, e0091521. doi: 10.1128/Spectrum.00915-21, PMID: - DOI - PMC - PubMed
    1. Cecil A. J., Sogues A., Gurumurthi M., Lane K. S., Remaut H., Pak A. J. (2024). Molecular dynamics and machine learning stratify motion-dependent activity profiles of S-layer destabilizing nanobodies. PNAS Nexus 3, 538. doi: 10.1093/pnasnexus/pgae538, PMID: - DOI - PMC - PubMed

MeSH terms

Substances